Outcome of Board Meeting
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.5 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences reported FY 2025-26 audited results with revenue from operations at Rs 70,752 lakhs, up 8.3% from Rs 65,343 lakhs in the previous year. However, profit after tax declined significantly to Rs 11,517 lakhs from Rs 18,324 lakhs in the prior year, a drop of approximately 37%. This decline was largely due to much lower exceptional items in the current year (Rs 390 lakhs) compared to the previous year (Rs 8,260 lakhs), which included a large one-time gain from assignment of surplus land. The Board recommended a dividend of Rs 24 per equity share (300% on face value of Rs 8). The statutory auditor gave an unmodified (clean) opinion with no qualifications.
The stock may face pressure due to the 37% PAT decline despite steady revenue growth. However, the clean audit opinion, dividend declaration, and strong cash position (cash and equivalents rose to Rs 15,046 lakhs from Rs 2,870 lakhs) provide some stability for shareholders. The prior year's large exceptional gain from land sale created a high base effect.